Nauman Khalid, MD
Interventional Cardiology · Monroe, LANPI 1821336405
Payments from drug & device makers
Across 587 payments — averaging $75.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Philips North America LLC$13K
- Abbott$4K
- Abiomed$3K
- Inari Medical, Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$924
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$1,6005%
- Travel & lodging$15,33149%
- Food & beverage$14,17845%
- Education$3781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 75 | $16,264 |
| Philips North America LLC | 3 | $12,894 |
| Abbott | 46 | $4,238 |
| Abiomed | 75 | $3,004 |
| Inari Medical, Inc. | 16 | $1,232 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 72 | $924 |
| Novartis | 55 | $628 |
| Amgen | 27 | $481 |
| Johnson & Johnson(2 entities) | 33 | $471 |
| Actelion Pharmaceuticals US, Inc. | 22 | $424 |
| Atricure, Inc. | 10 | $367 |
| Pfizer | 18 | $313 |
| Zimmer Biomet | 7 | $300 |
| Shockwave Medical, Inc | 12 | $289 |
| Boehringer Ingelheim | 18 | $288 |
| AstraZeneca | 5 | $256 |
| Kowa Pharmaceuticals America, Inc. | 10 | $200 |
| Boston Scientific | 5 | $198 |
| Stryker | 7 | $178 |
| Merck | 10 | $173 |
| Sanofi-aventis U.S. LLC | 9 | $166 |
| Bayer | 8 | $152 |
| Cvrx, Inc. | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 8 | $123 |
| Lexicon Pharmaceuticals, Inc. | 5 | $88 |
| Irhythm Technologies, Inc. | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $72 |
| Scpharmaceuticals Inc. | 4 | $69 |
| Edwards Lifesciences | 2 | $62 |
| Chiesi USA, Inc. | 2 | $50 |
| Novo Nordisk | 2 | $31 |
| Livanova USA, Inc. | 1 | $29 |
| Penumbra, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Itamar Medical Inc | 1 | $20 |
| Terumo Medical Corporation | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Endologix LLC | 1 | $17 |
| Cardiovascular Systems Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$11,977
- AVEIR$1,905
- MitraClip$1,232
- Impella$1,221
- CoreValve Evolut$988
- FLOWTRIEVER CATHETER, S$860
- CT THROMBECTOMY SYSTEM KIT$860
- Repatha$249
- Resolute$213
- AZURE XT DR MRI SURESCAN$149
- IN.PACT Admiral$147
- Barostim Neo System$112
- WATCHMAN Access System$104
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$103
How this compares
$44,356 in reported general payments places this provider in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 77 | $63,506 |
| EliquisApixaban | 44 | $34,505 |
| Repatha SureclickEvolocumab | 44 | $29,006 |
| JardianceEmpagliflozin | 19 | $14,629 |
| Metoprolol Succinate | 87 | $1,173 |
| ClopidogrelClopidogrel Bisulfate | 71 | $658 |
| Mexiletine Hcl | 13 | $633 |
| Amiodarone Hcl | 33 | $458 |
| Flecainide Acetate | 13 | $422 |
| Rosuvastatin Calcium | 20 | $395 |
| Atorvastatin Calcium | 20 | $289 |
| Potassium Chloride | 12 | $260 |
| Spironolactone | 35 | $250 |
| Losartan Potassium | 29 | $248 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $628 | $63,50677 claims |
| PfizerEliquis | $313 | $34,50544 claims |
| Boehringer IngelheimJardiance | $288 | $14,62919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Monroe
- Mark NapoliMonroe$2.2M
- Gregory SampognaroMonroe$43K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
- James JenkinsNew Orleans$1.2M
- Ankur LodhaLafayette$945K
- Rajan PatelNew Orleans$633K
- Bruce EnnisMandeville$562K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.